BioCentury | Mar 4, 2017
Product Development

Diagnosing AD trials

...beta-site APP-cleaving enzyme (BACE) inhibitor in Phase III trials for early and mild AD; and MEDI1814...
BioCentury | Dec 17, 2016
Product Development

Not dead yet

...doubled down on the hypothesis by licensing co-development and co-commercialization rights to AstraZeneca plc ’s MEDI1814...
...Center and director of the Alzheimer’s Disease Research Center at Columbia University . Unlike solanezumab, MEDI1814...
BioCentury | Dec 16, 2016
Company News

AstraZeneca, Eli Lilly deal

...AstraZeneca and Eli Lilly partnered to co-develop MEDI1814 . AZ will receive $30 million up front...
...AstraZeneca plc (LSE:AZN; NYSE:AZN), London, U.K. Eli Lilly and Co. (NYSE:LLY), Indianapolis, Ind. Business: Neurology Chris Lieu AZD3293 LY2062430 LY3314814 MEDI1814 solanezumab AstraZeneca...
BioCentury | Dec 15, 2016
Financial News

Lilly raises guidance, launches Basaglar

...charge related to Lilly's deal with AstraZeneca plc (LSE:AZN; NYSE:AZN) announced last week to develop MEDI1814...
BioCentury | Dec 10, 2016
Company News

AZ, Lilly to co-develop selective amyloid mAb

...AstraZeneca plc (LSE:AZN; NYSE:AZN) and Eli Lilly and Co. (NYSE:LLY) said they partnered to co-develop MEDI1814...
Items per page:
1 - 5 of 5